Bio-Techne Corp Operating Income 2010-2025 | TECH

Bio-Techne Corp operating income for the twelve months ending June 30, 2025 was $0.102B, a 50.53% decline year-over-year.

  • Bio-Techne Corp annual operating income for 2025 was $0.102B, a 50.53% decline from 2024.
  • Bio-Techne Corp annual operating income for 2024 was $0.207B, a 30.86% decline from 2023.
  • Bio-Techne Corp annual operating income for 2023 was $0.299B, a 0.79% increase from 2022.

Bio-Techne Corp Operating Income 2010-2025 | TECH

  • Bio-Techne Corp annual operating income for 2025 was $0.102B, a 50.53% decline from 2024.
  • Bio-Techne Corp annual operating income for 2024 was $0.207B, a 30.86% decline from 2023.
  • Bio-Techne Corp annual operating income for 2023 was $0.299B, a 0.79% increase from 2022.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$247.9B
Amgen (AMGN)$155B
Gilead Sciences (GILD)$141.4B
Vertex Pharmaceuticals (VRTX)$99.8B
Bristol Myers Squibb (BMY)$96.9B
GSK (GSK)$81.3B
CSL (CSLLY)$67.8B
Regeneron Pharmaceuticals (REGN)$62.2B
Alnylam Pharmaceuticals (ALNY)$59.5B
Argenex SE (ARGX)$43.3B
Insmed (INSM)$28.4B
BioNTech SE (BNTX)$24.8B
Royalty Pharma (RPRX)$21B
Biogen (BIIB)$20B
Incyte (INCY)$16.6B
Genmab (GNMSF)$16B
Genmab (GMAB)$15.9B
Illumina (ILMN)$15.3B
Ascendis Pharma (ASND)$11.8B
BioMarin Pharmaceutical (BMRN)$11.3B
Swedish Orphan Biovitrum (BIOVF)$10.9B
QIAGEN (QGEN)$10.7B
Exelixis (EXEL)$10.4B
Moderna (MRNA)$9.8B
Verona Pharma American Depositary Share (VRNA)$9.1B
Exact Sciences (EXAS)$8.8B
Halozyme Therapeutics (HALO)$8.6B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8.2B
Guardant Health (GH)$7.9B